deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02855944

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor: Foundation Medicine

Conditions Epithelial Ovarian Cancer Fallopian Tube Cancer Ovarian Cancer Peritoneal Cancer
Interventions Chemotherapy Rucaparib
Updated 24 times since 2017 Last updated: Jun 7, 2023 Started: Mar 1, 2017 Primary completion: Dec 3, 2020 Completion: Sep 16, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Epithelial Ovarian Cancer and Fallopian Tube Cancer, this trial is completed. The trial is conducted by Foundation Medicine and has accumulated 24 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Feb 2018 · 7 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Apr 2020 · 8 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jul 2023 — Oct 2023 [monthly]

    Completed PHASE3

▶ Show 19 earlier versions

  1. Apr 2023 — Jul 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Apr 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Aug 2019 — Apr 2020 [monthly]

    Recruiting PHASE3

  8. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  9. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE3

  10. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  11. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  12. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  13. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  14. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  15. Jul 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  16. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  17. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  18. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Foundation Medicine
  • pharmaand GmbH
Data source: pharmaand GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Arkhangelsk, Russia , Augusta, United States , Barcelona, Spain , Barretos, Brazil , Bialystok, Poland , Bologna, Italy , Brno, Czechia , Budapest, Hungary , Calgary, Canada and 58 more locations